10-Q: CONMED Reports Q2 2026 Results, Navigates Market Shifts

CONMED Corporation announced its second quarter 2026 financial results, showing modest revenue growth driven by its Orthopedic Surgery segment, while navigating strategic divestitures and debt management.

Summary

• CONMED Corporation reported net sales of $343.5 million for the three months ended June 30, 2026, a slight increase of 0.3% compared to the prior year period, and a decrease of 0.5% to $660.5 million for the six months ended June 30, 2026.
• The Orthopedic Surgery segment saw sales increase by 8.2% and 7.5% for the three and six-month periods, respectively, driven by growth in powered surgical instruments, sports medicine, visualization, and BioBrace products.
• General Surgery segment sales declined by 5.2% and 6.2% for the respective periods, largely due to the exit from gastroenterology product offerings, partially offset by growth in AirSeal and smoke evacuation products.
• Gross profit margins improved significantly, increasing by 250 basis points to 57.5% for the quarter and 57.7% for the six months, benefiting from IEEPA tariff refunds and the termination of a distribution agreement, despite charges related to product discontinuation.
• Selling and administrative expenses increased as a percentage of net sales, impacted by a loss on the sale of gastroenterology assets, advisory costs, and operational optimization expenses.
• The company repurchased $645.2 million in principal amount of its 2.250% convertible notes for $637.2 million, resulting in a gain on extinguishment.
• CONMED continues to manage its debt, with $683.0 million in variable rate debt outstanding under its senior credit agreement, and has $455.5 million in available borrowings on its revolving credit facility.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive report, with solid performance in the orthopedic segment and improved margins, balanced by a decline in general surgery revenue and increased operating expenses.

Positives

• Orthopedic Surgery segment sales showed strong growth of 8.2% for the quarter and 7.5% for the six months.
• Gross profit margins improved by 250 basis points to 57.5% for the quarter and 57.7% for the six months, indicating improved operational efficiency and favorable product mix.
• Received $10.2 million in IEEPA tariff refunds, with $8.5 million recorded in cost of goods sold, positively impacting cost of sales.
• Successfully repurchased a significant portion of its 2.250% convertible notes, resulting in a $8.1 million gain on extinguishment.
• Maintained compliance with debt covenants and restrictions under its senior credit agreement.
• Ended the quarter with $455.5 million in available borrowings on its revolving credit facility, providing strong liquidity.
• Net sales in Orthopedic Surgery increased by 8.2% in the three months ended June 30, 2026, driven by powered surgical instruments, sports medicine, visualization, and BioBrace products.

Negatives

• General Surgery segment sales declined by 5.2% for the quarter and 6.2% for the six months, primarily due to the exit from gastroenterology product offerings.
• Selling and administrative expenses increased as a percentage of net sales, impacting overall profitability.
• Recorded a $4.4 million loss on the sale of additional gastroenterology product offering assets.
• Research and development expenses increased by 4.5% for the quarter and 17.4% for the six months, indicating higher investment in product development.
• The company is experiencing higher manufacturing and operating costs due to inflationary pressures and supply chain challenges.
• Total assets decreased to $2,300.3 million from $2,325.7 million at the end of the previous year.

Risks

• General economic and business conditions, including potential economic downturns, supply chain challenges, inflation, and increased interest rates.
• Compliance with and changes in laws and regulatory requirements, including the European Union's Medical Device Regulations.
• The risk of information security breaches and cybersecurity threats.
• Pandemics and health crises and the responses thereto.
• Competition and changes in customer preferences and technology.
• Environmental compliance risks, including the availability of sterilization methods like Ethylene Oxide (EtO).
• The ability to defend and enforce intellectual property rights.
• Risks associated with patent, product, and other litigation.

Future Outlook

The company believes its existing cash, cash flows from operations, and available borrowing capacity will be sufficient to meet its future cash requirements for at least the next twelve months. Management also believes it could access capital markets to fund future business acquisitions. The company expects to repurchase at least $25.0 million in shares annually, with $61.8 million planned for 2026.

Management Comments

• The company sold certain assets related to its gastroenterology product offerings as part of its portfolio optimization strategy.
• CONMED will continue to manufacture certain gastroenterology products for the buyer for twelve months under a manufacturing and supply agreement.
• The company is experiencing higher manufacturing and operating costs due to inflationary pressures and ongoing supply chain challenges.
• Management believes that cash flow from operations, cash on hand, and available borrowing capacity will be adequate to meet anticipated requirements.
• The company may need to take further steps to reduce costs or refinance debt.

Industry Context

StockSavvy.ai notes that CONMED's performance reflects broader trends in the medical technology sector, including strategic portfolio adjustments and the ongoing impact of supply chain and inflationary pressures. The growth in orthopedic surgery aligns with increased demand for elective procedures, while the decline in general surgery highlights the challenges of divesting non-core assets.

Legal Proceedings

• In the ordinary course of business, involved in various legal actions including product liability, employment, intellectual property, commercial disputes, stockholder matters, environmental proceedings, tax disputes, and governmental proceedings and investigations.
• No expectation that the resolution of any pending claims will have a material adverse effect on financial condition, results of operations, or cash flows, but no assurance can be given for future claims.

Related Party Transactions

• Cash and stock-based compensation costs related to advisory services provided by former Chief Financial Officer ($3.3 million in six months ended June 30, 2026).
• Cash and stock-based compensation costs related to advisory services provided by former Chief Executive Officer ($12.2 million in six months ended June 30, 2025).

Stakeholder Impact

• Shareholders may benefit from improved gross margins and the share repurchase program, but face potential headwinds from increased operating expenses and strategic divestitures.
• Creditors are impacted by the significant repurchase of convertible notes and the company's debt levels, though covenants are currently met.
• Suppliers may face continued challenges due to ongoing supply chain issues and inflationary pressures.
• Employees may be impacted by the company's focus on operational optimization and cost management.

Next Steps

• Continue to monitor spending and expenses in light of inflationary pressures and supply chain challenges.
• Evaluate and propose improvements in manufacturing operations.
• Continue to monitor and adjust business strategy in response to global conflicts.
• Consider further steps to reduce costs or refinance debt if necessary.
• The Board of Directors will consider declaring dividends from time to time in the future.

Key Dates

Recommendation

The company shows resilience with improved margins and growth in its key orthopedic segment, alongside a significant debt management action. However, the decline in general surgery, increased operating expenses, and ongoing macroeconomic uncertainties suggest a 'hold' position until clearer growth trends emerge and the impact of strategic changes is fully realized.

Keywords

Medical Technology, Surgical Devices, Orthopedic Surgery, General Surgery, Convertible Notes, Debt Repurchase, Gross Profit Margin, Revenue Growth